Nordic Enterprises See SDN as Key to Network Agility, Working from Home
5.7.2021 11:00:00 EEST | Business Wire | Press release
Enterprises in the Nordics are expanding their adoption of software-defined networking technology to become more agile and flexible while enabling employees to more easily work from home, according to a new report published today by Information Services Group (ISG) (Nasdaq: III), a leading global technology research and advisory firm.
The 2021 ISG Provider Lens™ Network – Software Defined Solutions and Services Report for the Nordics finds enterprises in the region looking to SDN-related technologies and service providers to help them with challenges related to the flexibility, speed and collaboration they need to better serve their employees and their increasingly mobile customers.
“Nordic enterprises are looking to SDN and its service providers to increase their network agility, flexibility and competitiveness while enabling remote working and better business continuity,” said Jan Erik Aase, partner and global leader, ISG Provider Lens Research. “This new need for enterprise agility goes beyond the abilities of traditional networks in a constantly changing competitive environment.”
The report also sees enterprises in the region embracing SD-WAN to enable remote working. While WAN architecture at enterprises has created backhaul challenges, that architecture is evolving to support more connectivity choices. Vendors are enabling enterprises to use a variety of transport options actively or on standby.
In addition, Nordic enterprises are moving toward more automation and analytics. Enterprises are increasingly embracing the concept of the network as code, where changes in the network infrastructure can be handled through code changes. Service providers are leveraging automation tools and allowing visibility into the cloud, the data center, and the WAN. Nordic enterprises see SD-WAN as a way to drive automation, reduce reliance on network hardware and consolidate network functionality.
Nordic enterprises are also seeking end-to-end connectivity to analyze data at the edge, including data generated by Internet of Things (IoT) devices, the report says. Service providers and system integrators are exploring ways to bring new capabilities to Wi-Fi 6, long-term evolution (LTE) and fifth-generation (5G) networks. They are also looking to assist customers with large public 5G rollouts, with some spectrum potentially allocated for enterprises.
New SDN-related technologies will pave the way for the industrial IoT to scale up and for edge computing to grow further, the report adds. However, a more inclusive network ecosystem is needed for the cloud, which is evolving into a holistic web of network technologies that include components of SDN such as WAN, LAN and Wi-Fi 6 management.
The report also sees changes in network practices driven in part by the move in the Nordics to the cloud and to the software-as-a-service model. Enterprises there have been seeing more internet-based traffic, which has led them to consider new ways to look at connectivity. Enterprises are moving away from a conventional hub-and-spoke networking model and considering instead an any-to-any connectivity model that supports more cloud-oriented traffic patterns.
The 2021 ISG Provider Lens™ Network – Software Defined Solutions and Services Report for the Nordics evaluates the capabilities of 55 providers across six quadrants: Managed (SD) WAN Services, SDN Transformation Services (Consulting and Implementation), SD-WAN Equipment and Service Suppliers (DIY), Technology and Service Suppliers (Core – 4G/5G), Edge Technology and Services, and Enterprise 5G Solutions.
The report names Orange Business Services as a leader in five quadrants and BT, Cisco, Deutsche Telekom, HCL, IBM, Tech Mahindra and Wipro as leaders in four. Ericsson, HPE Aruba and Nuage Networks are named leaders in three quadrants, and Infosys, TCS, Telenor, Telia, Verizon and VMware are named leaders in two. Citrix, Juniper Networks, Nokia Networks and Versa Networks are named leaders in one quadrant.
In addition, Tech Mahindra, Verizon and Wipro were named Rising Stars—companies with “promising portfolios” and “high future potential” by ISG’s definition—in two quadrants. GTT and Infosys were named Rising Stars in one quadrant each.
The 2021 ISG Provider Lens™ Network – Software Defined Solutions and Services Report for the Nordics is available to subscribers or for one-time purchase on this webpage.
About ISG Provider Lens™ Research
The ISG Provider Lens™ Quadrant research series is the only service provider evaluation of its kind to combine empirical, data-driven research and market analysis with the real-world experience and observations of ISG's global advisory team. Enterprises will find a wealth of detailed data and market analysis to help guide their selection of appropriate sourcing partners, while ISG advisors use the reports to validate their own market knowledge and make recommendations to ISG's enterprise clients. The research currently covers providers offering their services globally, across Europe, as well as in the U.S., Germany, Switzerland, the U.K., France, the Nordics, Brazil and Australia/New Zealand, with additional markets to be added in the future. For more information about ISG Provider Lens research, please visit this webpage.
A companion research series, the ISG Provider Lens Archetype reports, offer a first-of-its-kind evaluation of providers from the perspective of specific buyer types.
About ISG
ISG (Information Services Group) (Nasdaq: III) is a leading global technology research and advisory firm. A trusted business partner to more than 700 clients, including more than 75 of the world’s top 100 enterprises, ISG is committed to helping corporations, public sector organizations, and service and technology providers achieve operational excellence and faster growth. The firm specializes in digital transformation services, including automation, cloud and data analytics; sourcing advisory; managed governance and risk services; network carrier services; strategy and operations design; change management; market intelligence and technology research and analysis. Founded in 2006, and based in Stamford, Conn., ISG employs more than 1,300 digital-ready professionals operating in more than 20 countries—a global team known for its innovative thinking, market influence, deep industry and technology expertise, and world-class research and analytical capabilities based on the industry’s most comprehensive marketplace data. For more information, visit www.isg-one.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210705005021/en/
Contact information
Will Thoretz, ISG
+1 203 517 3119
will.thoretz@isg-one.com
Erik Arvidson, Matter Communications for ISG
+1 617 755 2985
isg@matternow.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 20:52:00 EEST | Press release
International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release
Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom